After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using In-labeled octreotide.
Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Are you the author?
Department of Radiology and Biomedical Imaging; Division of Hematology/Oncology, Department of Medicine, Departments of Pathology, Urology, and Radiation Oncology, University of California San Francisco, San Francisco, CA.
Reference: Clin Nucl Med. 2015 Mar 17. Epub ahead of print.